MINI-ROCKET
M
Michelle C. Starr, MD
Primary Investigator
Enrolling By Invitation
1 years and younger
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
Determine differences in international practice patterns of neonatal and infant continuous kidney replacement therapy prescriptions and the relationship between dose and major adverse kidney events
Detailed description of study
The protocol
seeks to study the heterogeneity of CKRT dosing prescriptions for neonates and
infants with AKI, and whether CKRT prescription leads to increased losses of
important solutes that negatively impact short-term growth-related outcomes.
Our overarching hypothesis is that a higher CKRT dose will result in
significant solute (vitamins, minerals, amino acids) losses that will negatively
impact outcomes. Understanding dosing variability and its impact on outcomes
will lay the foundation for standardized dosing in neonatal and infant
CKRT.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kidney injury, Riley
-
Age: - 1 Years
-
Gender: All
Inclusion Criteria:
- · Receiving/plan to receive CKRT for the treatment of AKI and/or fluid overload· Weigh < 10 kg at screening/CKRT initiation· (For Aim 1 only) Included in WE-ROCK or the research arm of ICONIC
Exclusion Criteria:
- · Diagnosed congenital kidney failure· Receiving extracorporeal membrane oxygenation (ECMO) concurrently with CKRT· Previously received another form of dialysis during this same hospital admission (i.e. hemodialysis or peritoneal dialysis)
Updated on
14 Sep 2024.
Study ID: 16603; PNEPH-CCHMC-MINI-ROCKET
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
